These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17134795)

  • 1. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life.
    Guiso N; Njamkepo E; Vié le Sage F; Zepp F; Meyer CU; Abitbol V; Clyti N; Chevallier S
    Vaccine; 2007 Feb; 25(8):1390-7. PubMed ID: 17134795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
    Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
    Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.
    Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E
    Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory.
    Stenger RM; Smits M; Kuipers B; van Gaans-van den Brink J; Poelen M; Boog CJ; van Els CA
    Vaccine; 2010 Sep; 28(40):6637-46. PubMed ID: 20637762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator.
    Ladhani SN; Andrews NJ; Southern J; Jones CE; Amirthalingam G; Waight PA; England A; Matheson M; Bai X; Findlow H; Burbidge P; Thalasselis V; Hallis B; Goldblatt D; Borrow R; Heath PT; Miller E
    Clin Infect Dis; 2015 Dec; 61(11):1637-44. PubMed ID: 26374816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine.
    Edelman KJ; He Q; Makinen JP; Haanpera MS; Tran Minh NN; Schuerman L; Wolter J; Mertsola JA
    Clin Infect Dis; 2004 Jul; 39(2):179-85. PubMed ID: 15307026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination.
    Prelog M; Almanzar G; Rieber N; Ottensmeier B; Zlamy M; Liese J
    Vaccine; 2013 Jan; 31(2):387-93. PubMed ID: 23142306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-pertussis antibody kinetics following DTaP-IPV booster vaccination in Norwegian children 7-8 years of age.
    Aase A; Herstad TK; Jørgensen SB; Leegaard TM; Berbers G; Steinbakk M; Aaberge I
    Vaccine; 2014 Oct; 32(45):5931-6. PubMed ID: 25218299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins.
    Hendrikx LH; Oztürk K; de Rond LG; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
    Vaccine; 2011 Feb; 29(7):1431-7. PubMed ID: 21187178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
    Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
    Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model.
    Huh DH; Han SB; Shin HJ; Ahn DH; Choi GS; Kang KR; Kim BR; Kang JH
    J Microbiol Immunol Infect; 2018 Dec; 51(6):732-739. PubMed ID: 28720318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of chosen parameters of immuno response in mice immunized with whole-cell or acellular pertussis vaccines and challenged with B. pertussis strains harbouring different ptxS1/prn allele genes combinations].
    Gzyl A; Augustynowicz E; Zawadka M; Rabczenko D; Slusarczyk J
    Med Dosw Mikrobiol; 2007; 59(2):137-47. PubMed ID: 17929411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertussis specific cell-mediated immune responses ten years after acellular pertussis booster vaccination in young adults.
    Gröndahl-Yli-Hannuksela K; Kauko L; Van Der Meeren O; Mertsola J; He Q
    Vaccine; 2016 Jan; 34(3):341-9. PubMed ID: 26643932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertussis Vaccine Effectiveness in the Setting of Pertactin-Deficient Pertussis.
    Breakwell L; Kelso P; Finley C; Schoenfeld S; Goode B; Misegades LK; Martin SW; Acosta AM
    Pediatrics; 2016 May; 137(5):. PubMed ID: 27244813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster.
    Mallet E; Matisse N; Mathieu N; Langue J; Boisnard F; Soubeyrand B;
    Vaccine; 2004 Mar; 22(11-12):1415-22. PubMed ID: 15063564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
    Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fifth vaccination with dipthteria, tetanus and acellular pertussis is beneficial in four- to six-year-olds.
    Pichichero ME; Anderson EL; Rennels MB; Edwards KM; England JA
    Pediatr Infect Dis J; 2001 Apr; 20(4):427-33. PubMed ID: 11332669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.